Scheduling Note: Cost Curve is off tomorrow, back on Monday. Oh, we’re heavy into transparency report season now. I’ve dug up two additional sources for list- and net-price changes, which
It’s a big 340B day, starting with a decision by a federal appeals court to side with Arkansas in a dispute with PhRMA. Arkansas has a law that says that
Yesterday, I wrote about the State of the Union speech, noting that the Biden proposal to expand the number of medicines to face negotiations was weirdly meaningless (Biden wants 500
I’m back -- 100% back -- from last week, where I was super-sick on Wednesday, rallied for a 6 a.m. flight the next day, and closed on my new home
I woke up this morning not feeling myself. Per Binax, I’m technically fine, COVID-wise, but I was still thrown for a loop. I’d intended to take tomorrow off -- there’s
There were three big takeaways from yesterday’s White House “listening session” on PBMs: The White House wants the David vs Goliath narrative. Of the five non-government speakers, four represented pharmacies.
There are two ways of looking at the ruling against AstraZeneca in its IRA lawsuit. (If you want to catch up quick on the basics, Bloomberg Law has you covered.)
Look, there’s not much going on today, so I won’t waste your time with a lot of fluff. In the absence of actual news, I’m paying close attention to potential